As synthetic biology and AI capabilities continue to expand and combine, biosecurity threats are becoming both more widespread and more difficult to mitigate. This panel will discuss these challenges in the context of a recent positive case study, in which multiple organizations collaborated to address an AI-based biological "zero day" threat using practices adapted from cybersecurity. We will further discuss how this collaboration has since matured into a larger effort to develop international standards for nucleic acid biosecurity screening, and close with remarks on emerging challenges in biosecurity.